Corvus Pharmaceuticals (CRVS) Invested Capital: 2022-2025
Historic Invested Capital for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $71.8 million.
- Corvus Pharmaceuticals' Invested Capital rose 478.35% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.8 million, marking a year-over-year increase of 478.35%. This contributed to the annual value of $32.6 million for FY2024, which is 15.81% down from last year.
- Per Corvus Pharmaceuticals' latest filing, its Invested Capital stood at $71.8 million for Q3 2025, which was down 10.54% from $80.2 million recorded in Q2 2025.
- Over the past 5 years, Corvus Pharmaceuticals' Invested Capital peaked at $89.7 million during Q1 2022, and registered a low of $12.4 million during Q3 2024.
- Over the past 3 years, Corvus Pharmaceuticals' median Invested Capital value was $48.9 million (recorded in 2023), while the average stood at $46.6 million.
- As far as peak fluctuations go, Corvus Pharmaceuticals' Invested Capital tumbled by 71.98% in 2024, and later soared by 478.35% in 2025.
- Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Invested Capital stood at $56.1 million in 2022, then slumped by 31.06% to $38.7 million in 2023, then fell by 15.81% to $32.6 million in 2024, then surged by 478.35% to $71.8 million in 2025.
- Its Invested Capital stands at $71.8 million for Q3 2025, versus $80.2 million for Q2 2025 and $49.3 million for Q1 2025.